**Abstract**

**Importance:** Long-term sleep disturbances in menopausal women are closely related to cardiovascular disorders, metabolic disorders, and cognitive impairment. At present, hormone therapy (HT) is a standard treatment for menopausal symptoms. However, it remains unclear whether HT can improve sleep quality.

**Objective:** We did a systematic review and meta-analysis to assess the effects of different HT regimens on menopausal sleep quality.

**Evidence Review:** We systematically searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, PsycINFO, CINAHL, and Web of Science for randomized controlled trials of menopausal HT on sleep disturbances up to June 14, 2021. Information about ongoing and unpublished trials was collected by searching WHOICTRP and ClinicalTrials.gov. Our primary outcome was sleep quality with objective measurements. We estimated the standardized mean difference (SMD) using random-effects models.

**Findings:** We identified a total of 3,059 studies and finally included 15 studies in the meta-analysis. Compared with placebo, HT improved self-reported sleep outcomes (SMD = –0.13; 95% CI, –0.18 to -0.08, P = 0.00001 and I² = 41%), but not sleep parameters measured by polysomnography. Subgroup analyses according to the regimen of HT showed that 17β-estradiol (17β-E₂) (SMD = –0.34; 95% CI, –0.51 to –0.17, P < 0.0001, and I² = 0%) and conjugated equine estrogens (SMD = –0.10; 95% CI, –0.12 to –0.07, P < 0.00001, and I² = 0%) improved sleep quality. Moreover, transdermal administration (SMD = –0.35; 95% CI, –0.64 to –0.06, and P = 0.02) was more beneficial than oral (SMD = –0.10; 95% CI, –0.14 to –0.07, and P < 0.00001). In addition, the combination of estrogen and progesterone had a positive effect on sleep disturbance (SMD = –0.10; 95% CI, –0.13 to –0.07, P < 0.00001, and I² = 0%), while estrogen monotherapy did not. The results showed that estrogen/micronized progesterone (SMD = –0.22; 95% CI, –0.37 to –0.06, P = 0.007, and I² = 0%) and estrogen/medroxyprogesterone acetate (SMD = –0.10; 95% CI, –0.13 to –0.07, P < 0.00001, and I² = 0%) could alleviate sleep disturbance.

**Conclusions and Relevance:** HT has a beneficial effect on sleep disturbance to some extent, and the formulations and routes of administration of hormonal agents influence the effect size.

**Key Words:** Estrogen – Menopause – Progesterone – Sleep.

Sleep disturbance is one of the distinctive features of menopausal symptoms and a well-recognized global health problem.1,2 Compared to young women and their male counterparts, premenopausal women have major sleep disturbances.3,4 Self-reported sleep problems were reported to increase by 2 to 3.5 times in women during the menopausal transition.5 Forty to sixty percent of women report problems sleeping during perimenopause and postmenopause.6
Menopausal sleep disturbances are significantly associated with vasomotor symptoms, such as hot flashes and night sweats, and are two to three times more likely to increase the risk of depression. Furthermore, long-term sleep disturbances are closely related to cardiovascular and metabolic disorders, cognitive impairment, deficits in immune function, and even malignant tumors. Therefore, sleep disturbance is an important issue for menopausal women.

McEwen and Alves reported that estrogen acted on the areas of sleep regulation in the brain, and the change of estrogen was the primary factor for sleep disturbance. Progesterone also decreased during menopause, and accumulating clinical data demonstrated its actions on the central nervous system. The close relationship between sleep problems and decreased levels of reproductive hormones in menopausal women has led to consideration of hormone therapy (HT) for their relief. However, there is a lack of effective treatment at present.

Montplaisir et al observed improved sleep efficiency in the oral conjugated equine estrogens (o-CEE) plus micronized progesterone group, but not in the medroxyprogesterone acetate (MPA) group. Citron et al reported alleviated sleep disturbances in the transdermal 17β-estradiol (t-17β-E2) group and the o-CEE group. However, Heinrich and Wolf did not find beneficial effects of estradiol valerate (EV) or estradiol plus micronized progesterone on sleep quality. Due to the heterogeneity of the participants, different formulations and doses of HT, and different measurements for sleep quality in previous studies, there is no consistent evidence that HT could improve sleep quality. It is also unclear which is the most effective therapeutic regimen for improving sleep quality. Hence, synthesized evidence is needed to help women and clinicians to choose the most appropriate treatment for menopausal women with sleep disorders.

A previous meta-analysis found that HT improved sleep quality in postmenopausal women with vasomotor symptoms, nevertheless, it failed to compare the effects of different formulations of HT on sleep disorders with each other owing to the limited number of original studies. Besides, the study was short of the measurement and analysis of objective indicators for sleep disturbances. Therefore, with several newly-published clinical studies, we updated and optimized the previous meta-analysis, and also did a systematic review of randomized controlled trials (RCTs) to evaluate the effects of different formulations and routes of administration of HT on sleep disturbance, aiming to probe into the association between HT therapy and sleep disturbance in menopausal women and consequently take effective measures to promote the physical and mental health of menopausal women.

**METHODS**

This systematic review adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and was registered with the International Prospective Register of Systematic Reviews (PROSPERO), number CRD42021256551.

**Key Points**

**Question/Objective:** What are the effects of different regimens of hormone therapy (HT) on menopausal sleep quality?

**Findings:** Fifteen randomized controlled trials (n = 27,715) evaluating the effect of different regimens of HT on menopausal sleep quality were included. The present study demonstrated that HT improved subjective sleep quality in 12 randomized controlled trials. More specifically, 17β-estradiol (17β-E2) and conjugated equine estrogens improved sleep quality, whereas estradiol valerate did not. In addition, transdermal regimens were more beneficial than oral.

**Meaning:** Based on the meta-analysis, HT could improve sleep quality, and the formulations and routes of administration of hormonal agents influence the effect size.

**Search strategy and eligibility criteria**

We selected relevant studies in the following databases: MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, PsycINFO, CINAHL, and Web of Science. We developed a search strategy from text and MeSH terms related to "hormone replacement therapy," "estradiol," "progesterone," "menopause," "insomnia," and "sleep" up to June 14, 2021. Information about ongoing and unpublished trials was obtained by searching WHOICTRP and ClinicalTrials.gov.

We included studies that considered HT administration as either the treatment or the control group. We identified eligible studies according to the following criteria: participants had to be women during menopause, including perimenopause and postmenopause; minimal intervention length was 4 weeks; the outcomes were related to sleep quality measured with polysomnography or self-reported questionnaires; study design must be double-blind RCTs. Studies with HT at any dose, formulations, and routes of administration, such as oral, subdermal, transdermal, or intravenous, were eligible for inclusion. Exclusion criteria were as follows: observation and retrospective studies; studies in which HT was combined with compounds other than progesterone derived or selective estrogen receptor modulators; studies not published in English. For the overlapped sample sources, we included the report with more information and larger sample sizes.

Two independent investigators reviewed study titles and abstracts, and studies that satisfied the inclusion criteria were retrieved for full-text assessment. The agreement of both investigators determined final eligibility. Disagreements were referred to a third reviewer to reach a consensus.

**Data extraction and assessment of risk bias**

Two reviewers independently extracted the following data from each included study using a specifically designed form: study design, sample sizes, participant characteristics, details of HT, duration, and sleep outcomes. We extracted the mean...
and standard deviation for the result. Disagreements were referred to a third reviewer to reach a consensus.

Two independent reviewers assessed the included studies for risk of bias using the Cochrane risk of bias tool, containing seven specific domains. We resolved any disagreements by consensus or by a discussion with a third author. Each domain was assigned a judgment relating to the risk of bias for that study classified as low, high, or unclear risk.

**Statistical analysis**

Since the included studies used different scales to evaluate sleep quality, we calculated pooled estimates of the standardized mean differences (SMDs) and 95% confidence intervals (CIs) with a random-effects model. To overcome a unit-of-analysis error for multiarms studies, we combined groups to create a single pair-wise comparison. For most studies, lower scores indicated better sleep quality except five studies, in which we reversed the direction to keep consistent with the others. We assessed statistical heterogeneity using the $I^2$ statistic, with values greater than 50% regarded as moderate-to-high heterogeneity. We performed prespecified subgroup analyses according to the following parameters: formulation of HT; routes of administration of HT; and perimenopause or postmenopause. We did Egger tests to assess funnel plot asymmetry, and defined significant publication bias with the $P$ value lower than 0.1. We conducted sensitivity analyses to determine whether the conclusions were robust. We presented the overall quality of the evidence for each outcome using the GRADE criteria. We conducted the statistical analyses with the Review Manager (Revman5.3.3, Cochrane Collaboration, Copenhagen, Denmark, 2014) and Stata software (version 14.0, StataCorp LP, TX, 1985-2015).

**RESULTS**

**Search results**

In total, we identified 3,059 studies, and 2,224 studies remained after we removed duplicates. Subsequently, we excluded 2,132 studies after reviewing the titles and abstracts. Of the remaining 92 articles assessed for eligibility, 28 studies met the inclusion criteria. Nineteen studies reported sufficient data, whereas 15 with placebo arm as comparator were included in the quantitative analysis (Fig. 1).

![Flow diagram for study selection](image_url)
| Study design | Sample size | Participant characteristics | Details of HT (t/d) | Control | Duration | Sleep outcomes |
|-------------|-------------|----------------------------|--------------------|---------|----------|----------------|
| Brunner et al | 10,739 | postmenopausal women with hysterectomy, mean age 63.6 y | o-CEE 0.625 mg | placebo | 12 mo | WHIIRS |
| Cintron et al | 727 | postmenopausal women, mean age 52.6 y | o-CEE 0.45 mg + micronized progesterone 200 mg, t-17b-E2 50 μg + micronized progesterone 200 mg | placebo | 48 mo | PSQI |
| Enerud et al | 339 | menopause, postmenopausal or undergone hysterectomy, mean age 54.6 y | o-17β-E2 0.5 mg | placebo | 8 wk | PSQI |
| Hachul et al | 33 | postmenopausal women, mean age 56.4 y | o-CEE 0.625 mg | placebo | 24 wk | polysomnography |
| Heinrich and Wolf | 51 | postmenopausal women with hysterectomy, mean age 64.1 ± 0.6 y | o-EV 2 mg, o-EV 2 mg + micronized progesterone 200 mg | placebo | 24 wk | Sleep item from ASDK and from Menopausal Index Questionnaire |
| Kagan et al | 1,835 | postmenopausal women, mean age 55 y | oral TX-001HR (1 mg E2/100 mg P4, 0.5 mg E2/100 mg P4, 0.5 mg E2/50 mg P4, 0.25 mg E2/50 mg P4) | placebo | 12 mo | MOS-sleep questionnaire |
| Kalleinen et al | 18 | postmenopausal women, mean age 62.9 y | o-EV 2 mg + norethisterone 0.7 mg | placebo | 6 mo | BNSQ and polysomnography |
| LeBlanc et al | 37 | late menopausal or early postmenopausal women, mean age 52.3 y | o-E2 2 mg | placebo | 8 wk | OHSU SL sleep diary |
| Leeangkoonsathian et al | 100 | perimenopause, early menopause or late menopause women, mean age 52.1 ± 4.1 y | o-EV 1 mg + micronized progesterone 10 mg, o-EV 1mg + dydrogesterone 100 mg | placebo | 3 mo | PSQI |
| Meeuwsen et al | 85 | postmenopausal women, mean age 54.2 ± 4.7 y | o-tibolone 2.5 mg | placebo | 12 mo | NHP questionnaire |
| Polissen et al | 130 | postmenopausal women, mean age 52.6 ± 3.6 y | tibolone 2.5 mg, estradiol 1mg + norethindrone acetate 0.5 mg | placebo | 12 wk | WHQ sleep item |
| Polo-Kantola et al | 71 | postmenopausal women, mean age 56.4 ± 4.4 y | estradiol 2.5 g, estrogen patch 50 μg | placebo | 3 mo | polysomnography |
| Saletu-Zyhlarz et al | 55 | insomniac postmenopausal women, mean age 58 | o-E2 2 mg + dienogest 3 mg, o-EV 2 mg | placebo | 8 wk | PSQI and polysomnography |
| Sarvolainen-Peltonen et al | 150 | postmenopausal women, mean age 53.2 y | t-E2 1 mg, o-EV 2 mg, o-EV 2mg + MPA 5 mg | placebo | 6 mo | WHQ sleep item |
| Shulman et al | 845 | postmenopausal women ≥45 y | t-17β-E2/LNG (0.045 mg + 0.015 mg, 0.045 mg + 0.030 mg, 0.045 mg + 0.040 mg), t-17β-E2 | placebo | 1 y | WHQ sleep item |
| Silva et al | 12 | postmenopausal women, mean age 49.7 ± 4.4 y | 0.045 mg o-E2 1mg + trimetoprim 125 mg | placebo | 4 wk | polysomnography |
| Tansupwattikul et al | 40 | insomniac postmenopausal women, mean age 54.4 y | t-17β-E2 50 μg | placebo | 2 mo | ISI |
| Welton et al | 3,721 | postmenopausal women with or without subtotal hysterectomy, mean age 63.8 y | o-CEE 0.625 mg + MPA2.5 mg, o-CEE 0.625 mg + MPA 5mg | placebo | 12 mo | WHQ sleep item |

17β-E2, 17β-estradiol; ADSK, German short version of the Center for Epidemiological Studies Depression Scale; BNSQ, Basic Nordic Sleep Questionnaire; CEE, conjugated equine estrogens; E2, estradiol; EV, estradiol valerate; HT, hormone therapy; ISI, Insomnia Severity Index; LNG, levonorgestrel; MOS, Medical Outcomes Study; MPA, medroxyprogesterone acetate; NHP, Nottingham Health Profile; o-, oral; o-CEE, oral conjugated equine estrogen; OHSU SL, Oregon Health and Science University Sleep Laboratory; P4, progesterone; PSQI, Pittsburgh Sleep Quality Index; RCT, randomized controlled trials; t-, transdermal; TX-001HR, a single, oral softgel capsule that contains hormones that are biologically identical to endogenous 17β-estradiol and progesterone; VitD3, vitamin D3; WHIIRS, Women’s Health Initiative Insomnia Rating Scale; WHQ, Women’s Health Questionnaire.

**Description of included studies**

The meta-analysis contained 27,715 participants: 14,058 women in the intervention group and 13,657 in the control group. Mean age ranged from 49.7 ± 4.4 to 64.1 ± 0.6 years old. Polysomnography was used in five trials, and subjective sleep questionnaires were used in 12 trials to evaluate sleep disorders. Six studies included women with vasomotor symptoms. Only three studies reported adverse effects. Tansupwattikul et al demonstrated that the t-17β-E2 group experienced more breast pain and vaginal discharge than the placebo group. Welton et al reported 37% of women with vaginal bleeding in the o-CEE plus MPA group and 4% in the placebo group. Meeuwsen et al reported eight women with bleeding and eight with spotting in the tibolone group, and three women with bleeding and one with spotting in the placebo group.
Four RCTs could not be included in the quantitative analysis due to the absence of outcomes in the placebo group. Leeangkoonsathia et al.\textsuperscript{30} reported that both EV combined with micronized progesterone and dydrogesterone improved sleep quality, whereas no significant difference between the two groups. Shulman et al.\textsuperscript{34} demonstrated that both t-17β-E\textsubscript{2} monotherapy and three doses of combined 17β-E\textsubscript{2}/levonorgestrel transdermal system improved sleep quality, whereas no significant difference among those groups. Kagan et al.\textsuperscript{27} observed the beneficial effects of TX-001HR, an oral softgel capsule containing hormones that were biologically identical to endogenous 17β-E\textsubscript{2} and progesterone ranging from 0.25 mg E\textsubscript{2}/50 mg P\textsubscript{4} to 1 mg E\textsubscript{2}/100 mg P\textsubscript{4}, on MOS-sleep scores. Polissen et al.\textsuperscript{32} reported alleviated sleep disturbances in the tibolone and the estradiol plus norethindrone acetate groups.

**Risk of bias in included studies**

We assessed the risk of bias in all included studies, as demonstrated in Figure 2. Ten studies reported adequate methods for random sequence generation.\textsuperscript{16,20,21,24,25,28,29,33,35,36} Seven studies did not specify whether data collectors and outcome assessors were masked to treatment allocation.\textsuperscript{17,22,23,26,28,33,35} Two studies rated at low risk of bias,\textsuperscript{16,35} and four were judged to be at high risk because of incomplete outcome data or funded by industry.\textsuperscript{17,21,31,36}

**Primary outcomes**

Meta-analysis of polysomnography studies showed no significant improvement in sleep parameters in the HT group, including total sleep time (SMD = −0.14; 95% CI, −0.48 to 0.20, \( P = 0.43 \), and \( I^2 = 10% \)), sleep latency (SMD = −0.22; 95% CI, −0.57 to 0.13, \( P = 0.23 \), and \( I^2 = 0% \)), sleep efficiency (SMD = −0.09; 95% CI, −0.39 to 0.20, \( P = 0.54 \), and \( I^2 = 0% \)), and arousals number (SMD = −0.07; 95% CI, −0.42 to 0.28, \( P = 0.69 \), and \( I^2 = 0% \) (Fig. 3). These studies did not show any heterogeneity. However, we downgraded the evidence to low quality using GRADE criteria due to the few participants of the included studies (Supplemental Digital Content 1, http://links.lww.com/MENO/A904).

Pooled analysis of self-reported sleep outcomes of the 12 included studies showed the significant improvement of sleep quality in the HT group (SMD = −0.13; 95% CI, −0.18 to −0.08, and \( P < 0.00001 \)) (Fig. 4), with moderate between-study heterogeneity (\( I^2 = 41% \)). We downgraded the evidence to moderate quality because of some included studies’ unclear risk for allocation concealment (Supplemental Digital Content 2, http://links.lww.com/MENO/A905).

**Subgroup analysis**

In the postmenopausal subgroup, HT improved self-reported sleep quality (SMD = −0.10; 95% CI, −0.13 to −0.08, and \( P < 0.00001 \)) (Fig. 4), and there was no significant heterogeneity between studies (\( I^2 = 20% \)). Subgroup analysis on the basis of sample size suggested a favorable sleep quality improvement of HT in the large sample subgroup (SMD = −0.12; 95% CI, −0.17 to −0.08, \( P < 0.00001 \), and \( I^2 = 46% \)). We also conducted subgroup analyses based on the duration of studies and found that more than 6 months of HT improved sleep quality (SMD = −0.10; 95% CI, −0.13 to −0.08, \( P < 0.00001 \), and \( I^2 = 6% \)). Subgroup analyses by different regimens of HT showed that 17β-E\textsubscript{2} (SMD = −0.34; 95% CI, −0.51 to −0.17, \( P < 0.0001 \), and \( I^2 = 0% \)) and CEE (SMD = −0.10; 95% CI, −0.12 to −0.07, \( P < 0.00001 \), and \( I^2 = 0% \)) improved sleep quality, but EV had no positive effect (Fig. 4). Both oral and transdermal subgroup showed beneficial effects on sleep disturbances (oral: SMD = −0.10; 95% CI, −0.14 to −0.07, \( P < 0.00001 \), and \( I^2 = 17% \);
transdermal: SMD = -0.35; 95% CI, -0.64 to -0.06, \( P = 0.02 \), and \( I^2 = 18\% \), and the transdermal subgroup had a larger effect (Fig. 4). In addition, estrogen plus progesterone was an adequate intervention (SMD = -0.10; 95% CI, -0.13 to -0.07, \( P < 0.00001 \), and \( I^2 = 0\% \)), whereas estrogen monotherapy was not (SMD = -0.14; 95% CI, -0.40 to 0.12, \( P = 0.29 \), and \( I^2 = 57\% \) (Fig. 4). Furthermore, subgroup analysis of estrogen combined with different progesterone showed that both estrogen plus micronized progesterone (SMD = -0.22; 95% CI, -0.37 to -0.06, \( P = 0.007 \), and \( I^2 = 0\% \)) and estrogen plus MPA (SMD = -0.10; 95% CI, -0.13 to -0.07, \( P < 0.00001 \), and \( I^2 = 0\% \)) positively associated with sleep disturbances, whereas other progesterone did not (Fig. 4).

Sensitivity analysis
Tansupswatdikul et al\(^2\) measured subjective sleep quality with Insomnia Severity Index, which is quite different from other sleep questionnaires. We conducted a sensitivity analysis to assess the contribution of this study to the synthesized outcome. We generated similar pooled SMD and 95% CI with the removal of this study (SMD = -0.12; 95% CI, -0.17 to -0.08, \( P < 0.00001 \), and \( I^2 = 36\% \), thus indicating no significant influence of the trial on the overall estimation of self-reported sleep quality.

Publication bias
The funnel plots for self-reported sleep quality models and regression analyses of Egger’s test suggested publication bias in this analysis (Supplemental Digital Content 3, http://links.lww.com/MENO/A906; Supplemental Digital Content 4, http://links.lww.com/MENO/A907).

DISCUSSION
We performed the systematic review and meta-analysis to comprehensively analyze the effect of HT on sleep disturbance with both subjective and objective sleep outcomes. We included 15 RCTs with similar interventions and sufficient quantitative data for statistical pooling. The pooled effects of subjective sleep quality showed a significant improvement in...
the HT group. Our pooled results were stable, and the heterogeneity among studies was moderate.

We did subgroup analyses to eliminate heterogeneity and evaluate the effect of different regimens of HT on sleep quality. The results showed that both oral and transdermal regimens positively impacted sleep disturbance, and transdermal administration was more helpful. Both 17\(\beta\)-E2 and CEE improved sleep quality, whereas EV did not. Furthermore, we found more favorable sleep quality improvement in the 17\(\beta\)-E2 subgroup. Considering the 17\(\beta\)-E2 subgroup contained three RCTs and two of them compared transdermal 17\(\beta\)-E2 to placebo, we speculated that transdermal 17\(\beta\)-E2 administration led to better effects. The underlying mechanism may be that transdermal estrogen delivery avoids the first-pass effect, resulting in more stable serum estradiol level and higher bioavailability comparing with oral administration.

In the subgroup analysis, the large sample subgroup showed improved sleep quality. Since large sample studies were more likely to avoid sampling error and better represent the actual effect, this result revealed a beneficial effect of HT on sleep disturbance. Furthermore, in the subgroup analysis of the duration of studies, we found that more than 6 months
of HT improved sleep quality. Our results provide evidence for the clinical application of HT on menopausal sleep disturbances.

A previous study has proved the sedative and hypnotic effects of progesterone. Lancel et al demonstrated that progesterone metabolites could produce similar changes to sleep architecture as benzodiazepines. We conducted subgroup analyses to estimate the effect of progesterone on sleep quality. Estrogen plus progesterone alleviated sleep disturbance, but estrogen monotherapy did not. Furthermore, both the estrogen plus micronized progesterone group and the estrogen plus MPA group improved sleep quality, and the former showed a better effect. However, formulations of estrogen may be a confounding factor. Consistent with the study, Leeangkoonsathia et al reported improved sleep quality in the EV plus micronized progesterone group and the EV plus dydrogesterone group. Montplaisir et al observed improved sleep efficiency in the micronized progesterone group. In postmenopausal women taking estrogen, they also observed increased subjective sleep quality in the micronized progesterone and the MPA group. Together with our results, the evidence indicated the critical role of progesterone on sleep.

A previous meta-analysis favored oral micronized progesterone for sleep onset latency but not total sleep time or sleep efficiency. We also analyzed the effects of HT on different sleep parameters of polysomnography. Because previous studies showed significant improvements in other menopausal symptoms in women who received estrogen therapy for four weeks, we excluded the studies with HT less than four weeks. Our pooled results indicated that HT had no beneficial effects on sleep parameters in postmenopausal women, including total sleep time, sleep latency, sleep efficiency, and arousals.

In addition, the pooled-analysis outcomes of polysomnography were inconsistent with that of subjective sleep scores. The possible reasons may be as follows: first, the studies measured with polysomnography were conducted in small samples on one or few nights, the polysomnography without long-term monitoring might not always correlate with perceived sleep quality. Second, objective sleep outcomes were assessed only in a few studies. Therefore, the pooled analysis results may be dubious. Mansikkamaki et al demonstrated that subjective symptoms were vital to assess sleep quality. A previous systematic review also showed that patients reported measurements were highly predictive of sleep quality. A clinical guideline-recommended subjective sleep measurements as instruments to diagnose and evaluate chronic insomnia. However, self-reported sleep quality items have some defects, such as a lack of standardized assessment tools. It is of importance for standardizing sleep assessments tools in further study.

Limitations

There are several limitations of this systematic review and meta-analysis. First, the studies included in our meta-analysis may have publication bias. One of the underlying reasons may be that some studies meeting the eligibility criteria did not report sufficient data for quantitative analysis. The attempts to communicate with authors to obtain missing data were unsuccessful. Second, some of the evidence in this review cannot discern the magnitude of effect on sleep quality through indirect reduction of vasomotor symptoms, which was known to affect sleep quality. Third, since lacking original studies, our meta-analysis could not directly estimate the effects of different routes of administration and formulations of HT on sleep quality. Fourth, we found that more than 6 months of HT improved sleep quality, but the ideal timing for the duration of HT on sleep disturbance remains vague. Finally, several studies carried potential risks of bias, such as attrition bias and pharmaceutical industry funding. Despite this, our study provides a comprehensive review of the current literature guided by a prospectively registered protocol. Overall, the conclusions drawn from this review represent a current collation of best evidence.

CONCLUSIONS

In conclusion, HT has a beneficial effect on sleep disturbance to some extent, and the formulations and routes of administration of hormonal agents influence the effect size. Our findings from indirect evidence support the use of transdermal 17β-estradiol combined with micronized progesterone for at least 6 months in menopausal women with sleep disturbance. However, further head-to-head RCTs with multicenter and larger sample sizes are needed to evaluate the effects of different routes of administration and formulations of HT on sleep quality to provide direct evidence.

Acknowledgments: We are particularly grateful to Deying Kang for his revision in the methodological section.

REFERENCES

1. Tom SE, Kuh D, Guralnik JM, Mishra GD. Self-reported sleep difficulty during the menopausal transition: results from a prospective cohort study. Menopause 2010;17:1128-1135.
2. Rocha FL, Guerra HL, Lima-Costa MF. Prevalence of insomnia and associated socio-demographic factors in a Brazilian community: the Bambuí study. Sleep Med 2002;3:121-126.
3. Leger D, Guilleminault C, Dreyfus JP, Delahaye C, Paillard M. Prevalence of insomnia in a survey of 12,778 adults in France. J Sleep Res 2000;9:35-42.
4. Kravitz HM, Ganz PA, Bromberger J, Powell LH, Sutton-Tyrrell K, Meyer PM. Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition. Menopause 2003;10:19-28.
5. Kravitz HM, Zhao X, Bromberger JT, et al. Sleep disturbance during the menopausal transition in a multi-ethnic community sample of women. Sleep 2008;31:979-990.
6. Moline ML, Broch L, Zak R, Gross V. Sleep in women across the life cycle from adulthood through menopause. Sleep Med Rev 2003;7:155-177.
7. Kim MJ, Yim G, Park HY. Vasomotor and physical menopausal symptoms are associated with sleep quality. PLoS One 2018;13:e0192934.
8. Caruso D, Masci I, Cipollone G, Palagini L. Insomnia and depressive symptoms during the menopausal transition: theoretical and therapeutic implications of a self-reinforcing feedback loop. Maturitas 2019;123:78-81.
9. Pines A. Sleep duration and midlife women’s health. Climacteric 2017;20:528-530.
10. Luytser FS, Strollo PJ Jr, Zee PC, Walsh JK. Sleep: a health imperative. Sleep 2012;35:727-734.
HORMONE THERAPY FOR SLEEP QUALITY

11. McEwen BS, Alves SE. Estrogen actions in the central nervous system. *Endocer Rev* 1999;20:279-307.
12. Bernardi F, Pluchino N, Pieri M, et al. Progesterone and medroxyprogesterone acetate effects on central and peripheral allopregnanolone and beta-endorphin levels. *Neuroendocrinology* 2006;33:348-359.
13. Gruber CJ, Huber JC. Differential effects of progestins on the brain. *Maturitas* 2003;46 (Suppl 1):S71-S75.
14. Sarti CD, Chiantera A, Graziotto A, et al. Hormone therapy and sleep quality in women around menopause. *Menopause* 2005;12:545-551.
15. Montplaisir J, Lorrain J, Deneze R, Petit D. Sleep in menopause: differential effects of two forms of hormone replacement therapy. *Menopause* 2001;8:10-16.
16. Cintron D, Lahr BD, Bailey KR, et al. Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPs). *Menopause* 2018;25:145-153.
17. Heinrich AB, Wolf OT. Investigating the effects of estradiol or estradiol/progesterone treatment on mood, depressive symptoms, menopausal symptoms and subjective sleep quality in older healthy hysterectomized women: a questionnaire study. *Neuropsychobiology* 2005;52:17-23.
18. Buysses DJ. Sleep health: can we define it? Does it matter? *Sleep* 2014;37:9-17.
19. Cintron D, Lipford M, Larrea-Martilla L, et al. Efficacy of menopausal hormone therapy on sleep quality: systematic review and meta-analysis. *Endocr Dev* 2017;55:702-711.
20. Brunner RL, Gass M, Aragaki A, et al. Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women’s Health Initiative Randomized clinical trial. *Arch Intern Med* 2005;165:1976-1986.
21. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progesterin on health-related quality of life. *N Engl J Med* 2003;348:1839-1854.
22. Saletu-Zyhlarz G, Anderer P, Gruber G, et al. Insomnia related to menopause and hormone replacement therapy: sleep laboratory studies on baseline differences between patients and controls and double-blind, placebo-controlled investigations on the effects of a novel estrogen-progestogen combination (Climodien, Lafamme) versus estrogen alone. *J Sleep Res* 2003;12:239-254.
23. Savolainen-Peltonen H, Hautamaki H, Tuomikoski P, Ylikorala O, Mikkola TS. Health-related quality of life in women with or without hot flashes: a randomized placebo-controlled trial with hormone therapy. *Menopause* 2014;21:732-739.
24. Tanus-spreckels K, Chaiikuttisilpa S, Jainchariyatam N, Panyakhamlerd K, Jaisanumr C, Taechakraichana N. Effects of estrogen therapy on menopausal postmenopausal sleep quality regardless of vasomotor symptoms: a randomized trial. *Climacteric* 2015;18:198-204.
25. Ensrud KE, Guthrie KA, Hohensee C, et al. Effects of estradiol and venlafaxine on insomnia symptoms and sleep quality in women with hot flashes. *Sleep* 2015;38:97-108.
26. Hachul B, Hittencourt LR, Andersen ML, Haidar MA, Barcat EC, Tufik S. Effects of hormone therapy with estrogen and/or progesterone on sleep pattern in postmenopausal women. *Int J Gynecol Obstet* 2008;103:207-212.
27. Kagan R, Constantine G, Kaunitz AM, Bernick B, Mirkin S. Improvement in sleep outcomes with a 17beta-estradiol-progesterone oral capsule (TX-0011HR) for postmenopausal women. *Menopause* 2018;25:622-628.
28. Kallgren N, Polo O, Hirvonen SL, Jousten A, Polo-Kantola P. The effect of estrogen plus progesterin treatment on sleep: a randomized, placebo-controlled, double-blind trial in premenopausal and late postmenopausal women. *Climacteric* 2008;11:233-243.
29. LeBlanc ES, Neiss MB, Carello PE, Samuels MH, Janowsky JS. Hot flashes and estrogen therapy do not influence cognition in early menopausal women. *Menopause* 2007;14:191-202.
30. Leega koonsathian E, Pantarsi T, Chaovisitseree S, Morakot N. The effect of different progestogens on sleep in postmenopausal women: a randomized trial. *Gynecol Endocrinol* 2017;33:933-936.
31. Meeuwsen IB, Sammon MM, Duursma SA, Verhaar HJ. The influence of tibolone on quality of life in postmenopausal women. *Maturitas* 2002;41:35-43.
32. Polisseni AF, Andrade AT, Ribeiro LC, et al. Effects of a continuous-combined regimen of low-dose hormone therapy (oestradiol and norethindrone acetate) and tibolone on the quality of life in symptomatic postmenopausal women: a double-blind, randomised study. *Maturitas* 2013;74:172-178.
33. Polo-Kantola P, Erkola R, Jirala K, Pullinen S, Virtanen I, Polo O. Effect of short-term transdermal estrogen replacement therapy on sleep: a randomized, double-blind crossover trial in postmenopausal women. *Fertil Steril* 1999;71:873-880.
34. Shulman LP, Yankov V, Ulu K. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials. *Menopause* 2002;9:195-207.
35. Silva BH, Martinez D, Wender MC. A randomized, controlled pilot trial of hormone therapy for menopausal insomnia. *Arch Womens Ment Health* 2011;14:505-508.
36. Welton AJ, Vickers MR, Kim J, et al. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. *BMJ* 2008;337:a1190.
37. Arafat ES, Hargrove JT, Maxson WS, Desiderio DM, Wentz AC, Andersen RN. Sedative and hypnotic effects of oral administration of micronized progesterone may be mediated through its metabolites. *Am J Obstet Gynecol* 1988;159:1203-1209.
38. Lancel M, Faulhaber J, Holsboer F, Rupprecht R. Progesterone induces changes in sleep comparable to those of agonistic GABAA receptor modulators. *Am J Physiol* 1996;271:E763-E772.
39. Nolan BJ, Liang B, Cheung AS. Efficacy of micronized progesterone for sleep: a systematic review and meta-analysis of randomized controlled trial data. *J Clin Endocrinol Metab* 2021;106:942-951.
40. Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J. Initial 17beta-estradiol dose for treating vasomotor symptoms. *Obstet Gynecol* 2005;95:726-731.
41. Haas S, Walsh B, Evans S, Krahe M, Ravnikar V, Schi B. The effect of transdermal estradiol on hormone and metabolic dynamics over a six-week period. *Obstet Gynecol* 1988;71:671-676.
42. Ameratunga D, Goldin J, Hickey M. Sleep disturbance in menopause. *Intern Med J* 2012;42:742-747.
43. Kay DB, Buyse DJ, Germain A, Hall M, Monk TH. Subjective-objective sleep discrepancy among older adults: associations with insomnia diagnosis and insomnia treatment. *J Sleep Res* 2015;24:32-39.
44. Manskikamaki K, Raitanen J, Nygaard CH, et al. Sleep quality and aerobic training among menopausal women—a randomized controlled trial. *Maturitas* 2012;72:339-345.
45. Devine EB, Hakim Z, Green J. A systematic review of patient-reported outcome instruments measuring sleep dysfunction in adults. *Pharmacoepidemiol Drug Saf* 2005;23:898-912.
46. Schutte-Rodin S, Broch L, Buyse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. *J Clin Sleep Med* 2008;4:487-504.